V8 Peptides — Engineered Performance
Research Library
KPV and the PepT1 Transporter: Uptake Evidence
KPVPreclinical

KPV and the PepT1 Transporter: Uptake Evidence

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

Is KPV taken up by the PepT1 transporter? Published work in intestinal epithelial and immune cells reports that KPV acts through PepT1, a transporter that accepts di- and tripeptides, based on competition and radiolabelled-KPV kinetic experiments. PepT1 is absent from normal colon but reported in inflamed colon. This is cell-culture and mouse evidence only. For laboratory research use only.

Most peptides are too large or too polar to cross a cell membrane on their own. KPV is the exception that made researchers look closely at a transporter. The tripeptide Lys-Pro-Val is a plausible substrate for PepT1, a transporter that moves short peptides across the membrane of intestinal cells, and the published KPV work links its effects in gut-cell models to that uptake. This article explains the transporter, what the evidence for KPV uptake actually consists of, and how an in vitro uptake experiment is designed. For laboratory research use only; not for human consumption.

It is written for the bench: transport assays are easy to run badly. For the molecule itself, start with what is KPV and the KPV research overview; for the cell-signaling readouts that follow uptake, see the article on NF-κB evidence. The KPV research vials page lists Lys-Pro-Val as 5 mg and 10 mg lyophilized vials at ≥98% HPLC purity, and its research applications include peptide-transport experiments in intestinal epithelial cells.

What PepT1 is and what it accepts

PepT1 (gene name SLC15A1) is the transporter that absorbs the short peptides produced by protein digestion into the epithelial cells of the small intestine. It works as an electrogenic proton/peptide symporter and can transport essentially every possible di- and tripeptide, while neither free amino acids nor peptides of four or more residues are accepted as substrates; transport is enantio-selective, and the same transporter handles several peptide-like drugs [1]. A review of proton-coupled peptide transporters adds that PEPT1 and PEPT2 are expressed in intestine, kidney, choroid plexus and other tissues and accept many peptidomimetic compounds, and it proposes a flowchart for identifying whether a compound is a substrate [2].

For KPV, the relevant fact is size: three residues put it inside the substrate range. That is a reason to test, not proof, because substrate recognition also depends on side-chain properties, charge and the terminal groups. A well-designed study therefore measures uptake directly, as described below.

Where PepT1 is found, and why that matters for model choice

PepT1 shows a strict axial gradient: highest in the proximal small intestine and absent from the colon in normal tissue. A study of human colonic tissue reported that hPepT1 expression occurs aberrantly in the colon with chronic ulcerative colitis and Crohn's disease, but not in normal colon or in colon with microscopic colitis [3]. The same study used Caco2-BBE cells, which resemble small-intestinal cells, and HT29-Cl.19A cells, which resemble colonic cells, so the two lines differ in transporter expression [3].

SystemPepT1 status as reportedImplication for a KPV uptake experiment
Small intestine (tissue)Highest expression [3]Physiological site of dietary di/tripeptide uptake
Normal colon (tissue)No expression [3]Uptake via PepT1 would not be expected
Inflamed colon in chronic disease (tissue)Aberrant expression reported [3]Possible entry route for tripeptides in that state
Caco2-BBE cellsSmall-intestine-like; used to characterize uptake [3, 4]Positive-control line for transporter-dependent uptake
HT29-Cl.19A cellsColonic-like; transporter-poor unless engineered [3]Negative-control line, or a line to transfect with the transporter

The published KPV uptake evidence

The central study measured uptake in two complementary ways. In competition experiments, unlabelled KPV was used as a competitor for a radiolabelled PepT1 substrate; in kinetic experiments, tritiated KPV was used to determine the characteristics of its uptake. The authors concluded that KPV acts via PepT1 expressed in immune and intestinal epithelial cells, that nanomolar concentrations of KPV inhibited activation of NF-κB and MAP kinase signaling and reduced cytokine secretion, and that oral administration reduced the incidence of DSS- and TNBS-induced colitis in mice [4]. The question of how the animal results connect to uptake is covered in the articles on colitis models.

The study's own design illustrates the two evidence types that any uptake claim needs: competition (does KPV block uptake of a known substrate, and does a known substrate block KPV?) and direct kinetics (can the compound's own transport be measured, with concentration, time and saturation?). Without both, an assertion that a peptide is a PepT1 substrate is incomplete.

Designing an in vitro uptake experiment

A minimal uptake design has five parts, each answering a specific question.

  1. A transporter-positive and a transporter-poor cell line. Caco2-BBE and HT29-Cl.19A were used in the published work, and the pair gives a built-in contrast [3, 4].
  2. A defined monolayer. Caco-2 cells grown on permeable supports develop morphologic characteristics of enterocytes and were characterized as a model for small-intestinal epithelial transport, with measurable transepithelial electrical resistance [5]. Resistance and a paracellular marker confirm that the layer is intact before any uptake is attributed to a transporter.
  3. A competitor. A known di/tripeptide substrate at excess concentration tests whether KPV entry is shared with that route.
  4. A direct measure. Labelled peptide, or an analytical method such as LC-MS on cell lysates, to see the compound itself.
  5. Controls for non-specific loss. Cells-free wells, to account for peptide sticking to plastic, and a time zero.

Transporter assays usually depend on the proton gradient, so the pH of the incubation buffer is a parameter that needs to be stated; the review of PepT1 describes the transport as a proton/peptide symport [1]. Report the buffer, pH, temperature, incubation time and cell passage.

Common pitfalls in peptide uptake work

PitfallWhy it misleadsRemedy
Peptide lost to tube and plate surfacesRecovery depends strongly on surface material; a study of radiolabelled peptides found large differences between plastics and glass [7]Run cell-free recovery controls; choose containers deliberately
Degradation in mediumPeptidases in serum or on cell surfaces can cleave the peptide before uptakeUse serum-free uptake buffer where possible; verify intact peptide by HPLC
Confusing binding with uptakePeptide stuck to the membrane is counted as cell-associatedInclude a cold-temperature or acid-wash control
Wrong cell modelColonic-like cells lack the transporter unless engineered [3]Pair a positive and a negative line
Unstated peptide contentCounterions and water make the weighed mass differ from net peptideReport the basis of concentration calculations
Assuming monolayer integrityLeaky layers allow paracellular passage that looks like transportMeasure resistance and a paracellular marker [5]

Reading the results

Uptake data usually appear as a saturation curve: transport rises with substrate concentration and levels off. Michaelis-Menten parameters, Km and Vmax, summarize the affinity and capacity of the transport, and a competitor shifts the apparent Km if the two compounds share the same site. A result with no saturation and no competition suggests passive entry. The concentration arithmetic for the dilution series is a formula: C1V1 = C2V2 for each step, with a stock concentration equal to vial mass divided by diluent volume. The reconstitution calculator handles the stock; the series belongs in the notebook, and the molecular weight of about 342.4 g/mol converts mass to molar units.

The nanomolar activity in the signaling readouts raises a quantitative question that an uptake assay can address: how much peptide has to enter the cell to account for the effect? Comparing intracellular KPV with the concentration in the medium, if the former is much higher, would indicate active accumulation. That comparison was not reported in the abstracts cited here and remains an experiment for a lab to run.

What the transporter does not explain

PepT1 uptake is a route into a cell, not a mechanism of action. After entry, KPV must still interact with something, and the bronchial-cell work, for example, describes nuclear import of KPV and an interaction with p65 as part of its mechanism [8], without relying on PepT1 in that report. Because normal colon lacks the transporter [3], the nanoparticle-in-hydrogel studies proposed bringing KPV to colonocytes in a carrier, with the authors reporting similar efficacy at a much lower KPV concentration than free solution [6]. That work is described in the article on nanoparticle and hydrogel delivery.

The limits are simple to state. The uptake evidence is from cultured cells; the transporter's expression varies with tissue and disease state; and the studies do not address intact human tissue. For the broader KPV literature see KPV research overview, for the antimicrobial results see KPV antimicrobial background, and for identity and purity documentation see KPV purity testing, how to read a COA and the COA page; for the single-peptide handling that precedes any assay, see how to reconstitute a lyophilized peptide.

Frequently asked questions

What is PepT1?

A proton-coupled peptide transporter in intestinal epithelial cells that moves di- and tripeptides across the membrane.

Is KPV a PepT1 substrate?

The published gut-cell work reported that KPV acts via PepT1, based on competition and tritiated-KPV kinetic experiments.

Which peptides can PepT1 carry?

Essentially every di- and tripeptide, but not free amino acids or peptides of four or more residues.

Why compare Caco2-BBE and HT29-Cl.19A cells?

Caco2-BBE cells resemble small-intestinal cells and express the transporter; HT29-Cl.19A cells are colonic-like and give a contrast.

Is PepT1 present in healthy colon?

No. A study reported no expression in normal colon but aberrant expression in colon from chronic ulcerative colitis and Crohn's disease.

What does a competition experiment show?

Whether KPV reduces uptake of a known substrate, indicating shared entry. It should be paired with a direct measure of KPV itself.

Why measure transepithelial resistance?

To confirm the cell layer is intact, so paracellular leakage is not mistaken for transporter-mediated uptake.

Does uptake explain the anti-inflammatory readouts?

No. Uptake is a route into the cell; the downstream mechanism is a separate question, and other routes were reported in other cells.

How do I handle peptide loss to plastic?

Run cell-free recovery controls and choose container materials deliberately, since recovery varies between surfaces.

Does this apply to people?

No. The work is in cultured cells and mice.

Related reading: KPV Peptide Explained: Sequence, Structure and Pathways, KPV Lab Handling: Reconstitution and Storage Steps, KPV Tripeptide Chemistry: Formula, Synthesis, Analysis.

References

  1. Daniel H. Molecular and Integrative Physiology of Intestinal Peptide Transport. Annu. Rev. Physiol.. 2004;66(1):361-384. doi:10.1146/annurev.physiol.66.032102.144149
  2. Brandsch M. Transport of drugs by proton-coupled peptide transporters: pearls and pitfalls. Expert Opinion on Drug Metabolism & Toxicology. 2009;5(8):887-905. doi:10.1517/17425250903042292
  3. Merlin D, Si-Tahar M, Sitaraman SV, Eastburn K, Williams I, Liu X, et al. Colonic epithelial hPepT1 expression occurs in inflammatory bowel disease: Transport of bacterial peptides influences expression of MHC class 1 molecules. Gastroenterology. 2001;120(7):1666-1679. doi:10.1053/gast.2001.24845
  4. Dalmasso G, Charrier–Hisamuddin L, Thu Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166-178. doi:10.1053/j.gastro.2007.10.026
  5. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology. 1989;96(3):736-749. PMID: 2914637
  6. Laroui H, Dalmasso G, Nguyen HTT, Yan Y, Sitaraman SV, Merlin D. Drug-Loaded Nanoparticles Targeted to the Colon With Polysaccharide Hydrogel Reduce Colitis in a Mouse Model. Gastroenterology. 2010;138(3):843-853.e2. doi:10.1053/j.gastro.2009.11.003
  7. Goebel-Stengel M, Stengel A, Taché Y, Reeve JR. The importance of using the optimal plasticware and glassware in studies involving peptides. Analytical Biochemistry. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
  8. Land SC. Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptides: mechanism of KPV action and a role for MC3R agonists. Int J Physiol Pathophysiol Pharmacol. 2012;4(2). PMID: 22837805

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.